What does Inductive Bio do?
Inductive Bio is a technology company that democratizes artificial intelligence models for small molecule drug discovery. The firm has developed a collaborative AI platform that accelerates compound optimization by mapping key ADMET properties.
How much did they raise?
The company raised $25M in a Series A round led by Obvious Ventures, with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, Amino Collective, and several angel investors including Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit.
What are their plans for the money?
Inductive Bio intends to use the funds to expand its AI model R&D and grow its pre-competitive data consortium. This expansion is expected to streamline the drug discovery process, enabling faster identification and optimization of development candidates.
What have they achieved so far?
The company has already shown promising results in a collaboration with Nested Therapeutics, where its platform helped resolve permeability and metabolic stability challenges, contributing to the nomination of a promising drug development candidate.
